Lead Product(s) : Lasofoxifene,Abemaciclib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Sermonix Pharma receives Chinese approval of IND application for lasofoxifene
Details : HLX78 (lasofoxifene) receives approval to join the ongoing global registrational ELAINE-3 trial with responsibility in China for the treatment of ER+/HER2 ESR1-mutated Breast Neoplasms.
Brand Name : HLX78
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 08, 2024
Lead Product(s) : Lasofoxifene,Abemaciclib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Lasofoxifene,Abemaciclib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Ligand Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Lasofoxifene is an investigational, nonsteroidal selective estrogen receptor modulator (SERM), which has been studied in previous comprehensive Phase 1-3 non-oncology clinical trials in more than 15,000 postmenopausal women worldwide.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 14, 2022
Lead Product(s) : Lasofoxifene,Abemaciclib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Ligand Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Lasofoxifene
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Objective response rate was 13.2% for lasofoxifene vs. 2.9% for fulvestrant, P=0.12, with 1 confirmed complete response (CR) (72-week duration) and 4 confirmed partial responses (PR) in the lasofoxifene arm vs. 1 PR in the fulvestrant arm.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 13, 2022
Lead Product(s) : Lasofoxifene
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Lasofoxifene
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The project will investigate the effects of lasofoxifene on unique models of endometrial cancer that carry ESR1 mutations. Sermonix is currently enrolling patients in two Phase 2 Evaluation of Lasofoxifene in ESR1 Mutations studies within the breast canc...
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 21, 2021
Lead Product(s) : Lasofoxifene
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Lasofoxifene,Abemaciclib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Eli Lilly
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The open-label, multi-center study will evaluate the safety of lasofoxifene in combination with abemaciclib for the treatment of pre- and postmenopausal women with locally advanced metastatic estrogen receptor-positive (ER+)/HER2- breast cancer and an ES...
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 13, 2020
Lead Product(s) : Lasofoxifene,Abemaciclib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Eli Lilly
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Lasofoxifene,Abemaciclib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Sermonix
Deal Size : Undisclosed
Deal Type : Partnership
Details : With the recent Health Canada agreement to proceed, the open-label, randomized Evaluation of Lasofoxifene in ESR1 Mutations (ELAINE 1, NCT03781063) study will now include Exactis Network sites in Quebec, Ontario, Nova Scotia and New Brunswick.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 30, 2020
Lead Product(s) : Lasofoxifene,Abemaciclib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Sermonix
Deal Size : Undisclosed
Deal Type : Partnership
LOOKING FOR A SUPPLIER?